CR8698A - Anticuerpos monoclonales al factor de crecimiento de hepatocito - Google Patents

Anticuerpos monoclonales al factor de crecimiento de hepatocito

Info

Publication number
CR8698A
CR8698A CR8698A CR8698A CR8698A CR 8698 A CR8698 A CR 8698A CR 8698 A CR8698 A CR 8698A CR 8698 A CR8698 A CR 8698A CR 8698 A CR8698 A CR 8698A
Authority
CR
Costa Rica
Prior art keywords
growth factor
hepatocite
monoclonal antibodies
pharmaceutical composition
administering
Prior art date
Application number
CR8698A
Other languages
English (en)
Inventor
Kyung Jin Kim
Yi-Chi Su
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8698(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Publication of CR8698A publication Critical patent/CR8698A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invencion es concerniente con un anticuerpo monoclonal neutralizante al factor crecimiento de hepatocito, una composicion farmaceutica que comprende el mismo y metodo de tratamiento que comprenden administrar tal composicion farmaceutica a un paciente, tal como para inhibir glioblastoma.
CR8698A 2004-04-15 2006-10-19 Anticuerpos monoclonales al factor de crecimiento de hepatocito CR8698A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/825,060 US20040208876A1 (en) 2003-04-18 2004-04-15 Monoclonal antibodies to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
CR8698A true CR8698A (es) 2007-12-17

Family

ID=35320045

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8698A CR8698A (es) 2004-04-15 2006-10-19 Anticuerpos monoclonales al factor de crecimiento de hepatocito

Country Status (25)

Country Link
US (5) US20040208876A1 (es)
EP (2) EP1734995B1 (es)
JP (2) JP4594381B2 (es)
KR (1) KR101072736B1 (es)
CN (1) CN1964738A (es)
AT (1) ATE473760T1 (es)
AU (1) AU2004319276C1 (es)
BR (1) BRPI0418745A (es)
CA (1) CA2563080C (es)
CR (1) CR8698A (es)
CY (1) CY1110783T1 (es)
DE (1) DE602004028168D1 (es)
DK (1) DK1734995T3 (es)
ES (1) ES2346886T3 (es)
HR (1) HRP20100521T1 (es)
IL (1) IL178474A (es)
MX (1) MXPA06011822A (es)
NO (1) NO20065227L (es)
NZ (1) NZ550324A (es)
PL (1) PL1734995T3 (es)
PT (1) PT1734995E (es)
RU (1) RU2361879C2 (es)
SI (1) SI1734995T1 (es)
WO (1) WO2005107800A1 (es)
ZA (1) ZA200609407B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
MXPA06000508A (es) * 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
AU2005267720B2 (en) * 2004-08-05 2012-02-23 Genentech, Inc. Humanized anti-cmet antagonists
MX2007015056A (es) * 2005-06-02 2008-03-11 Galaxy Biotech Llc Metodos para el tratamiento de tumores de cerebro con anticuerpos.
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
JP5191235B2 (ja) 2005-10-21 2013-05-08 中外製薬株式会社 心疾患治療剤
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AR057941A1 (es) * 2005-11-25 2007-12-26 Univ Keio Agentes terapeuticos para el cancer de prostata
AR059213A1 (es) 2006-01-27 2008-03-19 Univ Keio Agentes terapeuticos para enfermedades que involucran neovascularizacion coroidal
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CA2648644C (en) 2006-04-07 2016-01-05 Osaka University Muscle regeneration promoter
ES2378097T3 (es) 2006-06-02 2012-04-04 Aveo Pharmaceuticals, Inc. Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
ATE495195T1 (de) 2006-06-02 2011-01-15 Aveo Pharmaceuticals Inc Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
WO2009002521A2 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
MX2010012290A (es) * 2008-05-14 2011-02-21 Amgen Inc Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
CN101555912B (zh) * 2009-04-29 2012-10-03 深圳市特辰科技股份有限公司 一种转轮式自锁安全制动装置及其工作方法
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
EP4115906A1 (en) 2010-05-28 2023-01-11 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
JP2013537918A (ja) 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
BR112013030472A2 (pt) 2011-06-30 2019-09-24 Genentech Inc formulação farmacêutica, artigo de fabricação e método
CZ303636B6 (cs) * 2011-08-19 2013-01-23 Invos, Spol. S R. O. Biokontejner pro sber bioodpadu a komunálního odpadu
US20140234328A1 (en) 2011-09-09 2014-08-21 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
WO2013043452A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
WO2014010586A1 (ja) 2012-07-10 2014-01-16 武田薬品工業株式会社 注射用製剤
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
WO2014153166A2 (en) * 2013-03-14 2014-09-25 Alder Biopharmaceuticals, Inc. Therapeutic use of antibodies to hgf
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
CN121358764A (zh) * 2023-05-05 2026-01-16 布坦坦研究所 人抗FGF2单克隆抗体(mAb)、包含其的药物组合物、其用途和用于检测包含所述mAb的生物样品中的癌症的试剂盒

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US722041A (en) * 1902-11-24 1903-03-03 Mail Belting Company Conveyer-belt.
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
GB9003621D0 (en) 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9110202D0 (en) * 1991-05-10 1991-07-03 Erba Carlo Spa Truncated forms of the hepatocyte growth factor(hgf)receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
JP2000515735A (ja) * 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
WO2000012560A1 (en) 1998-08-28 2000-03-09 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
AU2002355249A1 (en) 2001-07-26 2003-02-17 Eli Lilly And Company Interleukin-1 beta antibodies
AU2002357388A1 (en) 2001-12-27 2003-07-24 The United States Of America, As Represented By The Department Of Veterans Affairs Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
EP1636593B9 (en) 2003-06-06 2009-12-16 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
DE602004024536D1 (de) 2003-07-07 2010-01-21 Van Andel Res Inst Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors
MXPA06000508A (es) * 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
MX2007015056A (es) * 2005-06-02 2008-03-11 Galaxy Biotech Llc Metodos para el tratamiento de tumores de cerebro con anticuerpos.
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
EP2204191A1 (en) 2010-07-07
EP1734995A1 (en) 2006-12-27
ZA200609407B (en) 2008-07-30
WO2005107800A1 (en) 2005-11-17
PL1734995T3 (pl) 2010-12-31
ATE473760T1 (de) 2010-07-15
AU2004319276B2 (en) 2010-08-26
US7494650B2 (en) 2009-02-24
ES2346886T3 (es) 2010-10-21
US7687063B2 (en) 2010-03-30
BRPI0418745A (pt) 2007-12-11
CA2563080A1 (en) 2005-11-17
CA2563080C (en) 2015-01-27
CN1964738A (zh) 2007-05-16
SI1734995T1 (sl) 2010-09-30
EP1734995A4 (en) 2007-04-25
US20120064066A1 (en) 2012-03-15
US20080019966A1 (en) 2008-01-24
DE602004028168D1 (de) 2010-08-26
CY1110783T1 (el) 2015-06-10
IL178474A0 (en) 2007-02-11
EP1734995B1 (en) 2010-07-14
JP2007532643A (ja) 2007-11-15
US20070160613A1 (en) 2007-07-12
JP2011012067A (ja) 2011-01-20
KR101072736B1 (ko) 2011-10-11
US20040208876A1 (en) 2004-10-21
HK1094167A1 (en) 2007-03-23
PT1734995E (pt) 2010-08-18
AU2004319276C1 (en) 2011-03-03
RU2361879C2 (ru) 2009-07-20
NO20065227L (no) 2007-01-10
MXPA06011822A (es) 2007-03-23
JP4594381B2 (ja) 2010-12-08
AU2004319276A1 (en) 2005-11-17
IL178474A (en) 2011-04-28
US20090104192A1 (en) 2009-04-23
DK1734995T3 (da) 2010-10-25
RU2006140257A (ru) 2008-05-20
HRP20100521T1 (hr) 2010-10-31
NZ550324A (en) 2009-12-24
KR20070012711A (ko) 2007-01-26

Similar Documents

Publication Publication Date Title
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
EA030259B8 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
EA201100694A1 (ru) Антитело к cd38 человека и его применение
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
EP1885399A4 (en) HUMANIZED ANTIBODIES TO CD40 AND METHOD FOR THEIR USE
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
ATE437186T1 (de) Anti-epcam-immunoglobuline
TR200902344T1 (tr) Anti-epidermal büyüme faktörü reseptör antikorları ile terapinin etkisinin geliştirilmesi için terapötik bileşimler.
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
ATE503476T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
UA98756C2 (ru) Антитело, которое связывается с cd38, для лечения заболевания, опосредованного cd38